The European Commission (EC) approved the Janssen Pharmaceutical Companies of Johnson & Johnson application for Byannli, a twice-yearly injection of paliperidone palmitate (PP6M), for the maintenance treatment of schizophrenia in adults who are clinically stable on one-monthly paliperidone palmitate (PP1M) or three-monthly paliperidone palmitate (PP3M). The approval is based on results from the Route 6 Study, which showed that 92.5% of consumers treated with PP6M were relapse-free at the end of the 12-month study. EC approval is valid in all 27 member states of the European Union, and the European Economic Area countries (Norway, Iceland, and Liechtenstein). The EC approval…
Content Restricted

You must be a Free or Elite member to view this resource.

Log In | Sign up or learn more about membership options.

Login to access The OPEN MINDS Circle Library. Not a member? Create your free account now!